Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion.
Ischemic-type biliary lesions (ITBLs) lead to considerable morbidity after orthotopic liver transplantation (OLT). The exact pathogenesis is unknown. We tested the hypothesis that insufficient perfusion of biliary arterial vessels might be responsible for ITBLs. This could be prevented by improved perfusion techniques. Since February 2000, we performed a controlled study using arterial back-table pressure perfusion (AP) to achieve reliable perfusion of the biliary-tract capillary system, which may be impaired by the high viscosity of University of Wisconsin solution. We retrospectively analyzed 190 OLTs performed between September 1997 and July 2002 with regard to ITBLs. One hundred thirty-one grafts were preserved by in situ standard perfusion (SP), including portal perfusion, whereas in 59 cases, additional AP was performed. Donor-related factors, recipient age, indication for OLT, OLT technique, immunosuppression, and ischemia time were similar in both groups. In the SP group, 21 of 131 patients (16%) developed ITBLs. Only 1 of 59 patients with grafts receiving AP developed ITBLs. This difference was highly significant (P =.004). Peak aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels within the first 3 days were significantly lower in the AP group (AST, P =.016; ALT, P =.007). Multivariate analysis showed a significant influence of AP (P =.010) and donor age (P =.003) on the development of ITBLs. AP is an easy and reliable method to prevent ITBLs in OLT. It therefore should be used as the standard technique in liver procurement.
Moench
Christian
C
Department of Transplantation and Hepatobiliary Surgery, Johannes Gutenberg-University Mainz, Germany. christian.moench@planet-interkom.de
Moench
Kerstin
K
Lohse
Ansgar W
AW
Thies
Jochen
J
Otto
Gerd
G
D000241:Adenosine; D000328:Adult; D000368:Aged; D000493:Allopurinol; D001652:Bile Ducts / Q000098:blood supply; D005978:Glutathione; D006084:Graft Rejection / Q000188:drug therapy / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin; D008107:Liver Diseases / Q000401:mortality* / Q000601:surgery; D016031:Liver Transplantation; D008875:Middle Aged; D019188:Organ Preservation Solutions; D010477:Perfusion / Q000379:methods*; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control; D011312:Pressure; D011887:Raffinose; D015427:Reperfusion Injury / Q000401:mortality* / Q000517:prevention & control*; D012189:Retrospective Studies; D015996:Survival Rate; D014783:Viscosity
D007166:Immunosuppressive Agents; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose